Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Guidance rank: #51 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Lincoln Pharmaceuticals Ltd Q2 FY27 key numbers
- Revenue
- Revenue from Operations for the quarter ended Sept 30, 2026: Rs. 19,134.51 Lakhs.
As stated in Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement · published 29 Oct 2026. Reported figures, not investment advice.
Based on Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from Operations for the quarter ended Sept 30, 2026: Rs. EBITDA for the quarter ended 30/09/2026: Rs.
From Lincoln Pharmaceuticals Ltd's Q2 FY27 earnings-call transcript · updated 29 Oct 2026.
Revenue & Sales Performance
Profitability & Margins
See what Lincoln Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Company has a state-of-the-art manufacturing facility unit at Khatraj, Ahmedabad, Gujarat, complying with international quality norms and certifications (EUGMP, TGA, WHO-GMP, ISO certifications).
- Plans to expand global footprint from 60+ countries to 90 countries over the next 2-3 years.
- Recent entry into Canadian market and approvals from TGA-Australia and EUGMP position company for further global expansion.
- Manufacturing unit and product portfolio expansion focus on robust portfolio building in lifestyle and chronic segments, especially women's healthcare and dermatology.
2 more points from Lincoln Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Lincoln Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Lincoln Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.
Lincoln Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹191 Cr, net profit ₹20 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Lincoln Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY
- Aarti Pharmalabs Ltd (Q2 FY27)
19,211.62 lakhs (~45.9% increase) . Key investor presentation takeaways from Aarti Pharmalabs Ltd's Q2 FY27 investor presentation — and how it ranks against sec
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Lincoln Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Lincoln Pharmaceuticals Ltd Q2 FY27 results?
Revenue from Operations for the quarter ended Sept 30, 2026: Rs. EBITDA for the quarter ended 30/09/2026: Rs.
What is Lincoln Pharmaceuticals Ltd share price analysis?
Lincoln Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 10.6 with a market cap of ₹1,021 Cr. Investors should review the full earnings analysis for detailed insights.
Is Lincoln Pharmaceuticals Ltd planning capital expenditure?
Company has a state-of-the-art manufacturing facility unit at Khatraj, Ahmedabad, Gujarat, complying with international quality norms and certifications (EUGMP, TGA, WHO-GMP, ISO certifications).
Keep Lincoln Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.